{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:49:06Z","timestamp":1753890546572,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19). However, evidence regarding its real-world effectiveness and safety profile remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effectiveness and safety of azvudine in COVID-19 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included 192 COVID-19 patients hospitalized in Fengtai District, Beijing, from November 1 to December 31, 2022. Patients were divided into azvudine (n=118) and non-azvudine (n=74) groups. Propensity score matching (PSM) was applied to balance baseline characteristics (age, sex, vaccination status, etc.), yielding 48 matched pairs. Outcomes included time to SARS-CoV-2 RNA negativity, hospitalization duration, and symptom resolution (fever, cough). Adverse events were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After PSM, 48 pairs of COVID-19 patients were identified. The azvudine group exhibited significantly shorter hospitalization than the non-azvudine group (median: 8 vs. 10 days, <jats:italic>P \u2264<\/jats:italic> 0.05). No significant differences were observed in time to RNA negativity (4.23 vs. 4.52 days, <jats:italic>P<\/jats:italic>&amp;gt;0.05), fever duration (2 vs. 2 days, <jats:italic>P<\/jats:italic>&amp;gt;0.05), or cough duration (4.5 vs. 5 days, <jats:italic>P<\/jats:italic>&amp;gt;0.05). One case of mild gastrointestinal discomfort was reported in the azvudine group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Azvudine significantly reduced hospitalization duration in mild-to-moderate COVID-19 patients with a favorable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1584261","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:41:50Z","timestamp":1750225310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching"],"prefix":"10.3389","volume":"15","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/v15071515","article-title":"Effectiveness of oral nirmatrelvir\/ritonavir vs. Intravenous three-day remdesivir in preventing progression to severe COVID-19: A single-center, prospective, comparative, real-life study","volume":"15","author":"Basoulis","year":"2023","journal-title":"Viruses."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20153","article-title":"Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"B3","unstructured":"Circular on the issuance of a protocol for the diagnosis and treatment of novel coronavirus infections (Trial 10th edition)\n          \n          2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1016\/j.jinf.2023.03.023","article-title":"Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19","volume":"86","author":"Gao","year":"2023","journal-title":"J. Infect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.19803\/j.1672-8629.20230357","article-title":"The latest progress of small molecule anti-SARS-CoV-2 drugs","volume":"20","author":"Ma","year":"2023","journal-title":"Chin. J. Pharmacovigilance"},{"key":"B6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1126\/science.abi5224","article-title":"Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets","volume":"373","author":"Maio","year":"2021","journal-title":"Science."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28660","article-title":"Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study","volume":"95","author":"Mazzitelli","year":"2023","journal-title":"J. Med. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm801595c","article-title":"The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4\u2019-azidocytidine against hepatitis C virus replication: the discovery of 4\u2019-azido-2\u2019-deoxy-2\u2019-fluorocytidine and 4\u2019-azido-2\u2019-dideoxy-2\u2019,2\u2019-difluorocytidine","volume":"52","author":"Smith","year":"2009","journal-title":"J. Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/jmv.26264","article-title":"RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1274294","article-title":"Head-to-head comparison of azvudine and nirmatrelvir\/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e00204","DOI":"10.1128\/JVI.00204-20","article-title":"The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses","volume":"94","author":"Xu","year":"2020","journal-title":"J. Virol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100321","article-title":"The first Chinese oral anti-COVID-19 drug Azvudine launched","volume":"3","author":"Yu","year":"2022","journal-title":"Innovation (Camb)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.13412\/j.cnki.zyyl.20220608.004","article-title":"Efficacy of jinyebaidu granule and lianhuaqingwen capsule in the treatment of severe COVID-19 patients:A retrospective cohort study adjusted with propensity score matching","volume":"39","author":"Yu","year":"2023","journal-title":"Pharmacol. Clinics Chin. Materia Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Immunol."},{"key":"B15","article-title":"Clinical effectiveness evaluation of Azvudine in mild and moderate high-risk patients with COVID-19 infection","volume":"43","author":"Zhang","year":"2023","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3851\/IMP2292","article-title":"Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates","volume":"17","author":"Zhou","year":"2012","journal-title":"Antivir Ther."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1228548","article-title":"Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1584261\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:41:53Z","timestamp":1750225313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1584261\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":18,"alternative-id":["10.3389\/fcimb.2025.1584261"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1584261","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1584261"}}